p.105 抽出テキスト

911. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens 2008;26:1636–41. https://doi.org/10.1097/HJH.0b013e3283018333 912. Staessen JA, Thijs L, Ohkubo T, Kikuya M, Richart T, Boggia J, et al. Thirty years of research on diagnostic and therapeutic thresholds for the self-measured blood pressure at home. Blood Press Monit 2008;13:352–65. https://doi.org/10.1097/ MBP.0b013e3283108f93 913. Kario K, Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens 2004;26:177–89. https://doi.org/10.1081/ceh-120028556 914. Tan X, Sundström J, Lind L, Franzon K, Kilander L, Benedict C, et al. Reverse dipping of systolic blood pressure is associated with increased dementia risk in older men: a longitudinal study over 24 years. Hypertension 2021;77:1383–90. https://doi.org/10.1161/ hypertensionaha.120.16711 915. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens 2014;28:463–8. https://doi.org/10.1038/jhh.2013.140 916. Denker MG, Haddad DB, Townsend RR, Cohen DL. Blood pressure control 1 year after referral to a hypertension specialist. J Clin Hypertens (Greenwich) 2013;15: 624–9. https://doi.org/10.1111/jch.12146 917. Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S, Watkins LL, Craighead L, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation 2021;144:1212–26. https://doi.org/10. 1161/circulationaha.121.055329 918. Hung SC, Kuo KL, Peng CH, Wu C-H, Lien Y-C, Wang Y-C, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int 2014;85:703–9. https://doi.org/10.1038/ki.2013.336 919. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002;39:982–8. https://doi.org/10.1161/ 01.hyp.0000016176.16042.2f 920. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008;168:1159–64. https://doi.org/10.1001/archinte.168.11.1159 921. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015;65:1041–6. https://doi.org/10.1161/hypertensionaha. 114.05021 922. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012;59:1104–9. https://doi.org/ 10.1161/hypertensionaha.111.190637 923. Chen C, Zhu XY, Li D, Lin Q, Zhou K. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21694. https://doi.org/10.1097/md.0000000000021694 924. Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol 2017;233:113–7. https://doi.org/10. 1016/j.ijcard.2016.12.158 925. Bazoukis G, Thomopoulos C, Tsioufis C. Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. J Hypertens 2018;36:987–94. https://doi.org/10.1097/hjh. 0000000000001671 926. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013;31: 2094–102. https://doi.org/10.1097/HJH.0b013e3283638b1a 927. Desai R, Park H, Brown JD, Mohandas R, Pepine CJ, Smith SM. Comparative safety and effectiveness of aldosterone antagonists versus beta-blockers as fourth agents in patients with apparent resistant hypertension. Hypertension 2022;79:2305–15. https:// doi.org/10.1161/hypertensionaha.122.19280 928. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543–51. https://doi.org/10.1056/NEJMoa040135 929. Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebocontrolled trial. Lancet 2019;394:1540–50. https://doi.org/10.1016/s0140-6736(19) 32135-x 930. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab 2012;97:100–9. https://doi.org/10.1210/jc.2011-1537 931. Rossi GP, Maiolino G, Seccia TM. Adrenal venous sampling: where do we stand? Endocrinol Metab Clin North Am 2019;48:843–58. https://doi.org/10.1016/j.ecl. 2019.08.012 932. Wu X, Senanayake R, Goodchild E, Bashari WA, Salsbury J, Cabrera CP, et al. [(11)C] metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. Nat Med 2023;29: 190–202. https://doi.org/10.1038/s41591-022-02114-5 933. Lenzini L, Prisco S, Caroccia B, Rossi GP. Saga of familial hyperaldosteronism: yet a new channel. Hypertension 2018;71:1010–4. https://doi.org/10.1161/hypertensionaha. 118.11150 934. Parthasarathy HK, Ménard J, White WB, Young WF, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011;29:980–90. https://doi.org/10.1097/HJH.0b013e3283455ca5 935. Shagjaa T, Sanga V, Rossi GP. Skin hyperpigmentation due to post-surgical adrenal insufficiency regressed with the dexamethasone treatment. J Clin Med 2022;11:5379. https://doi.org/10.3390/jcm11185379 936. Sanga V, Lenzini L, Seccia TM, Rossi GP. Familial hyperaldosteronism type 1 and pregnancy: successful treatment with low dose dexamethasone. Blood Press 2021;30: 133–7. https://doi.org/10.1080/08037051.2020.1863771 937. Persu A, Touzé E, Mousseaux E, Barral X, Joffre F, Plouin P-F. Diagnosis and management of fibromuscular dysplasia: an expert consensus. Eur J Clin Invest 2012;42:338–47. https://doi.org/10.1111/j.1365-2362.2011.02577.x 938. Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953–62. https:// doi.org/10.1056/NEJMoa0905368 939. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370: 13–22. https://doi.org/10.1056/NEJMoa1310753 940. Bailey SR, Beckman JA, Dao TD, Misra S, Sobieszczyk PS, White CJ, et al. ACC/AHA/ SCAI/SIR/SVM 2018 appropriate use criteria for peripheral artery intervention: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. J Am Coll Cardiol 2019;73:214–37. https://doi.org/10.1016/j.jacc.2018.10.002 941. Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension 2010;56:525–32. https://doi.org/10.1161/ hypertensionaha.110.152918 942. Sanga V, Bertoli E, Crimì F, Barbiero G, Battistel M, Teresa Seccia M, et al. Pickering syndrome: an overlooked renovascular cause of recurrent heart failure. J Am Heart Assoc 2023;12:e030474. https://doi.org/10.1161/jaha.123.030474 943. Bhalla V, Textor SC, Beckman JA, Casanegra AI, Cooper CJ, Kim ESH, et al. Revascularization for renovascular disease: a scientific statement from the American Heart Association. Hypertension 2022;79:e128–43. https://doi.org/10. 1161/hyp.0000000000000217 944. Bravo E, Fouad-Tarazi F, Rossi G, Imamura M, Lin WW, Madkour MA, et al. A reevaluation of the hemodynamics of pheochromocytoma. Hypertension 1990;15: I128–131. https://doi.org/10.1161/01.hyp.15.2_suppl.i128 945. Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension 2023;80:e46–57. https://doi.org/10.1161/hyp. 0000000000000224 946. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244 947. Boulestreau R, van den Born BH, Lip GYH, Gupta A. Malignant hypertension: current perspectives and challenges. J Am Heart Assoc 2022;11:e023397. https://doi.org/10. 1161/jaha.121.023397 948. Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, et al. The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet 2023;402: 27–40. https://doi.org/10.1016/s0140-6736(23)00806-1 949. Moullaali TJ, Wang X, Sandset EC, Woodhouse LJ, Law ZK, Arima H, et al. Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. J Neurol Neurosurg Psychiatry 2022;93: 6–13. https://doi.org/10.1136/jnnp-2021-327195 950. Wang X, Di Tanna GL, Moullaali TJ, Martin R’ H, Shipes VB, Robinson TG, et al. J-shape relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: a pooled analysis of INTERACT2 and ATACH-II individual participant data. Int J Stroke 2022;17:1129–36. https://doi.org/10.1177/17474930211064076 951. Qureshi AI, Huang W, Lobanova I, Barsan WG, Hanley DF, Hsu CY, et al. Outcomes of intensive systolic blood pressure reduction in patients with intracerebral hemorrhage and excessively high initial systolic blood pressure: post hoc analysis of a randomized clinical trial. JAMA Neurol 2020;77:1355–65. https://doi.org/10.1001/ jamaneurol.2020.3075 952. Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev 2014;2014:CD000039. https://doi.org/10.1002/ 14651858.CD000039.pub3 Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026